PMID- 19011511
OWN - NLM
STAT- MEDLINE
DCOM- 20090901
LR  - 20151119
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
VI  - 18
IP  - 6
DP  - 2008 Dec
TI  - A pilot study with vincristine sulfate liposome infusion in patients with 
      metastatic melanoma.
PG  - 400-4
LID - 10.1097/CMR.0b013e328311aaa1 [doi]
AB  - Vincristine sulfate liposome infusion (VSLI) is a sphingomyelin/cholesterol 
      liposome encapsulated formulation of vincristine that results in an extended drug 
      circulation time and the potential for enhanced malignancy targeting, exposure, 
      and anticancer activity. We assessed the safety and activity of VSLI in patients 
      with metastatic melanoma. VSLI, to provide VCR 2.0 mg/m without dose capping, was 
      infused over 1 h every 2 weeks (one cycle). Safety, tumor response, and survival 
      were determined. Twenty-seven patients with metastatic melanoma of cutaneous 
      (n=19), uveal (n=4), mucosal (n=1), and unknown (n=3) primary were treated. 
      Twenty-five (93%) patients had received one or more prior lines of chemotherapy 
      and/or immunotherapy; 14 (48%) had received a vinblastine-containing regimen. 
      Hematologic adverse events (AEs) primarily manifested as grade 1/2 neutropenia. 
      Nonhematologic AEs primarily consisted of gastrointestinal and constitutional 
      symptoms of grade 1/2 severity. Grade 3 AEs included one case of paresthesia and 
      four cases of constipation. The disease control rate in 26 evaluable patients was 
      31%. One complete (uveal melanoma metastatic to lung) and two partial responses 
      (previously untreated cutaneous melanoma metastatic to the bone, brain, spleen 
      and lung, and another with melanoma of unknown primary involving the lung, liver, 
      and lymph node) were found. Five patients had stable disease. The median time to 
      progression was 1.9 months. The median survival was 9.6 months with 30% of the 
      patients alive at 1 year. VSLI was generally well tolerated and showed promising 
      antitumor activity against metastatic melanoma and uveal melanoma in particular. 
      A phase 2 trial to further elucidate the efficacy and safety of VSLI in 
      metastatic uveal melanoma is ongoing.
FAU - Bedikian, Agop Y
AU  - Bedikian AY
AD  - Department of Melanoma Medical Oncology, the University of Texas MD Anderson 
      Cancer Center, Houston, Texas 77030, USA. abedikia@mdanderson.org
FAU - Papadopoulos, Nicholas E
AU  - Papadopoulos NE
FAU - Kim, Kevin B
AU  - Kim KB
FAU - Vardeleon, Anna
AU  - Vardeleon A
FAU - Smith, Teresa
AU  - Smith T
FAU - Lu, Biao
AU  - Lu B
FAU - Deitcher, Steven R
AU  - Deitcher SR
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Liposomes)
RN  - 5J49Q6B70F (Vincristine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Phytogenic/*administration & dosage
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Liposomes/administration & dosage
MH  - Male
MH  - Melanoma/*drug therapy/secondary
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Pilot Projects
MH  - Skin Neoplasms/*drug therapy/pathology
MH  - Tomography, X-Ray Computed
MH  - Vincristine/*administration & dosage
EDAT- 2008/11/18 09:00
MHDA- 2009/09/02 06:00
CRDT- 2008/11/18 09:00
PHST- 2008/11/18 09:00 [pubmed]
PHST- 2009/09/02 06:00 [medline]
PHST- 2008/11/18 09:00 [entrez]
AID - 00008390-200812000-00004 [pii]
AID - 10.1097/CMR.0b013e328311aaa1 [doi]
PST - ppublish
SO  - Melanoma Res. 2008 Dec;18(6):400-4. doi: 10.1097/CMR.0b013e328311aaa1.